Avecho Biotechnology Ltd Market Cap ($35.54 Million)
Market Cap & Net Worth: Avecho Biotechnology Ltd (AVE)
Avecho Biotechnology Ltd market cap. Avecho Biotechnology Ltd (AU:AVE) has a market capitalization of $35.54 Million (AU$50.23 Million) as of November 5, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22952 globally and #830 in its home market, demonstrating a -7.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avecho Biotechnology Ltd's stock price AU$0.01 by its total outstanding shares 3863725873 (3.86 Billion). Also see Avecho Biotechnology Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Avecho Biotechnology Ltd Market Cap History (2015–2026)
Avecho Biotechnology Ltd market cap history from 2015 to 2026. Data shows change from $31.99 Million to $35.54 Million (-1.04% CAGR). Check Avecho Biotechnology Ltd (AVE) share price today for real-time trading data and today's change.
Avecho Biotechnology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avecho Biotechnology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Avecho Biotechnology Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
19.88x
Avecho Biotechnology Ltd's market cap is 19.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $77.37 Million | $1.59 Million | -$17.31 Million | 48.72x | N/A |
| 2017 | $49.21 Million | $1.15 Million | -$8.62 Million | 42.79x | N/A |
| 2018 | $13.67 Million | $1.25 Million | -$3.99 Million | 10.92x | N/A |
| 2019 | $10.94 Million | $4.24 Million | $849.96K | 2.58x | 12.87x |
| 2020 | $79.28 Million | $384.63K | -$2.63 Million | 206.12x | N/A |
| 2021 | $41.01 Million | $793.60K | -$3.42 Million | 51.67x | N/A |
| 2022 | $41.01 Million | $1.13 Million | -$2.34 Million | 36.32x | N/A |
| 2023 | $9.57 Million | $473.55K | -$3.44 Million | 20.21x | N/A |
| 2024 | $6.83 Million | $1.13 Million | -$3.12 Million | 6.03x | N/A |
| 2025 | $24.60 Million | $1.24 Million | -$4.42 Million | 19.88x | N/A |
Competitor Companies of AVE by Market Capitalization
Companies near Avecho Biotechnology Ltd in the global market cap rankings as of November 5, 2026. Also see Avecho Biotechnology Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Avecho Biotechnology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Avecho Biotechnology Ltd (2015–2026)
Market capitalization of Avecho Biotechnology Ltd from 2015 to today. Between 2015 and today, Avecho Biotechnology Ltd's market cap moved from $31.99 Million to $ 35.54 Million, with a yearly change of -1.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$35.54 Million | +44.44% |
| 2025 | AU$24.60 Million | +260.00% |
| 2024 | AU$6.83 Million | -28.57% |
| 2023 | AU$9.57 Million | -76.67% |
| 2022 | AU$41.01 Million | 0.00% |
| 2021 | AU$41.01 Million | -48.28% |
| 2020 | AU$79.28 Million | +625.00% |
| 2019 | AU$10.94 Million | -20.00% |
| 2018 | AU$13.67 Million | -72.22% |
| 2017 | AU$49.21 Million | -36.40% |
| 2016 | AU$77.37 Million | +141.88% |
| 2015 | AU$31.99 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Avecho Biotechnology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.54 Million USD |
| MoneyControl | $35.54 Million USD |
| MarketWatch | $35.54 Million USD |
| marketcap.company | $35.54 Million USD |
| Reuters | $35.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more